All In Biotech

Free tool

FAERS Monitor: Lorbrena

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 210868 or its brand name (Lorbrena, Lorlatinib). Reports on generic versions are filed under their own applications.

Reports

7,455

Serious

6,225

84% of reports

Hospitalization

1,619

Death reported

2,070

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • death1,486
  • neoplasm progression620
  • off label use457
  • hallucination447
  • weight increased433
  • blood cholesterol increased381
  • dyspnoea293
  • malignant neoplasm progression285
  • oedema280
  • fatigue273
  • oedema peripheral270
  • peripheral swelling229
  • neuropathy peripheral212
  • cognitive disorder206
  • memory impairment204

Reports by year received

View as table
YearReports
20162
20176
201856
2019552
2020508
2021595
2022692
2023918
20241,225
20251,565
20261,336

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,046,704 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
neoplasm progressionSignal62051.247.529,981
blood cholesterol increasedSignal38123.221.18,039
hallucinationSignal44716.815.46,623
oedemaSignal28014.613.03,535
cognitive disorderSignal20612.510.92,163
malignant neoplasm progressionSignal2857.97.01,706
neuropathy peripheralSignal2126.35.5942
oedema peripheralSignal2706.35.61,193
weight increasedSignal4335.55.01,588
deathSignal1,4864.94.74,757
peripheral swellingSignal2294.23.7558
memory impairmentSignal2044.23.7496
off label use4571.51.372
dyspnoea2931.51.343
fatigue2731.00.90

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.